Glaukos Corp stock (US3773221029): shares near recent highs as valuation comes into focus

Glaukos Corp shares on the NYSE traded around USD 125 on 06/05/2026, close to their recent intraday high, putting the ophthalmic medical technology group’s valuation metrics into the spotlight for investors in the United States and abroad.

Glaukos Corp shares were quoted at USD 125.73 on 06/05/2026 on the New York Stock Exchange, after trading between an intraday low of USD 120.61 and a high of USD 127.76 that day, according to Robinhood as of 06/05/2026.

The United States-based ophthalmic medical technology company, which is listed on the NYSE under the ticker GKOS, thus remained within sight of recent highs, implying a market capitalization of about USD 7.38 billion and a price-to-earnings ratio of roughly -36.97 on 06/05/2026 based on the same source, keeping the home-market valuation in clear focus for investors in US dollars.

As of: 05.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Glaukos Corp
• Sector/industry: Ophthalmic medical technology and pharmaceuticals
• Headquarters/country: Aliso Viejo, United States
• Core markets: United States and international ophthalmology markets
• Key revenue drivers: Therapies for glaucoma, corneal disorders and retinal diseases
• Home exchange/listing venue: New York Stock Exchange (GKOS)
• Trading currency: USD

Glaukos Corp: core business model

Glaukos Corp develops and commercializes specialized ophthalmic devices and pharmaceutical therapies aimed at treating glaucoma, corneal conditions and retinal diseases, with revenue primarily generated from innovative minimally invasive glaucoma surgery products and related eye-care solutions sold to eye surgeons and clinical providers.

Valuation metrics and multiples for Glaukos Corp

The current share price around USD 125 on 06/05/2026 places Glaukos Corp firmly in the mid-cap segment of the US medical technology space, with a market value of about USD 7.38 billion and a negative price-to-earnings ratio of roughly -36.97, according to Robinhood as of 06/05/2026, reflecting ongoing investments and losses rather than mature profitability.

Industry overviews from platforms such as WallStreetZen as of 06/2026 show Glaukos Corp listed among notable US medical device names with a share price indication of USD 121.69 and a market capitalization figure of about USD 7.15 billion, suggesting that the company trades at a premium valuation compared with some peers due to its focus on high-growth ophthalmic therapies and expectations for future revenue expansion, based on WallStreetZen as of 06/2026.

Conclusion

Glaukos Corp shares hovered near recent intraday highs on the New York Stock Exchange on 06/05/2026, giving the ophthalmic specialist a market capitalization of around USD 7 billion and highlighting its negative earnings-based valuation multiple. Against this backdrop, investors monitoring Glaukos Corp may focus on how upcoming clinical, regulatory and commercial milestones in glaucoma and corneal therapies could influence future revenue growth and potentially reshape valuation metrics over time.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.